European Committee on Antimicrobial Susceptibility Testing

Recommendations

Info

Moraxella catarrhalis EUCAST Clinical Breakpoint Tables v. 7.0, valid from 2017-01-01 Fluoroquinolones MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Ciprofloxacin 0.5 0.5 5 26 A 26 A Levofloxacin 1 1 5 26 A 26 A Moxifloxacin 0.5 0.5 5 23 A 23 A Nalidixic acid (screen) NA NA 30 23 B Note B Norfloxacin (uncomplicated UTI only) - - - - Ofloxacin 0.5 0.5 5 25 A 25 A Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. A. The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. B. Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. Aminoglycosides MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Amikacin IE IE IE IE Gentamicin IE IE IE IE Netilmicin IE IE IE IE Tobramycin IE IE IE IE Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. Glycopeptides and lipoglycopeptides MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Dalbavancin - - - - Oritavancin - - - - Teicoplanin - - - - Telavancin - - - - Vancomycin - - - - Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. Macrolides, lincosamides and streptogramins MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Azithromycin 0.25 1 0.5 1 Note A Note A Clarithromycin 0.25 1 0.5 1 Note A Note A Erythromycin 0.25 0.5 15 23 A 20 A Roxithromycin 0.5 1 1 1 Note A Note A Telithromycin 0.25 0.5 15 23 20 Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 1/A. Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. Clindamycin - - - - Quinupristin-dalfopristin - - - - 53
Moraxella catarrhalis EUCAST Clinical Breakpoint Tables v. 7.0, valid from 2017-01-01 Tetracyclines MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Doxycycline 1 1 2 1 Note A Note A Minocycline 1 1 2 1 30 25 A 22 A Tetracycline 1 1 2 1 30 28 A 25 A Tigecycline IE IE IE IE Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 1/A. Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. Oxazolidinones MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Linezolid - - - - Tedizolid - - - - Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. Miscellaneous agents (µg) (mm) S ≤ R > S ≥ R < Chloramphenicol 2 1 2 1 30 30 A 30 A Colistin - - - - Daptomycin - - - - Fosfomycin iv IE IE IE IE Fosfomycin oral - - - - Fusidic acid - - - - Metronidazole - - - - Mupirocin MIC breakpoint (mg/L) Disk content Zone diameter breakpoint Nitrofurantoin (uncomplicated UTI only) - - - - Nitroxoline (uncomplicated UTI only) - - - - Rifampicin - - - - Spectinomycin - - - - Trimethoprim (uncomplicated UTI only) - - - - Trimethoprim-sulfamethoxazole 2 0.5 1 1.25-23.75 18 15 Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 1/A. Breakpoints relate to topical use only. 2. Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. 54
Page 1 and 2:
European C
Page 3 and 4: Guidance on reading EUCAST Breakpoi
Page 5 and 6: Version 7.0, 2017-01-01 Acinetobact
Page 7 and 8: Enterobacteriaceae EUCAST Clinical
Page 13 and 14: Pseudomonas spp. EUCAST Clinical Br
Page 15 and 16: Pseudomonas spp. EUCAST Clinical Br
Page 17 and 18: Acinetobacter spp. EUCAST Clinical
Page 19 and 20: Acinetobacter spp. EUCAST Clinical
Page 21 and 22: Staphylococcus spp. EUCAST Clinical
Page 27 and 28: Enterococcus spp. EUCAST Clinical B
Page 29 and 30: Enterococcus spp. EUCAST Clinical B
Page 31 and 32: Streptococcus groups A, B, C and G
Page 37 and 38: Streptococcus pneumoniae EUCAST Cli
Page 43 and 44: Viridans group streptococci EUCAST
Page 45 and 46: Viridans group streptococci EUCAST
Page 47 and 48: Haemophilus influenzae EUCAST Clini
Page 53: Moraxella catarrhalis EUCAST Clinic
Page 57 and 58: Neisseria gonorrhoeae EUCAST Clinic
Page 59 and 60: Neisseria gonorrhoeae EUCAST Clinic
Page 61 and 62: Neisseria meningitidis EUCAST Clini
Page 63 and 64: Neisseria meningitidis EUCAST Clini
Page 65 and 66: Gram-positive anaerobes except Clos
Page 67 and 68: Gram-positive anaerobes except Clos
Page 69 and 70: Clostridium difficile EUCAST Clinic
Page 71 and 72: Gram-negative anaerobes EUCAST Clin
Page 73 and 74: Gram-negative anaerobes EUCAST Clin
Page 75 and 76: Listeria monocytogenes EUCAST Clini
Page 77 and 78: Pasteurella multocida EUCAST Clinic
Page 79 and 80: Corynebacterium spp. EUCAST Clinica
Page 81 and 82: Aerococcus sanguinicola and urinae
Page 83 and 84: Kingella kingae EUCAST Clinical Bre
Page 85 and 86: Mycobacterium tuberculosis EUCAST C
Page 87 and 88: PK/PD (Non-species related) breakpo
Page 89 and 90: PK/PD (Non-species related) breakpo
Page 91 and 92: Dosages EUCAST Clinical Breakpoint
Page 93 and 94: Dosages EUCAST Clinical Breakpoint
show all

European Committee on Antimicrobial Susceptibility Testing

Create successful ePaper yourself

Delete template?

Save as template?